COMBI-OGAB Trademark

Trademark Overview


On Friday, March 31, 2023, a trademark application was filed for COMBI-OGAB with the United States Patent and Trademark Office. The USPTO has given the COMBI-OGAB trademark a serial number of 79372347. The federal status of this trademark filing is REGISTERED as of Tuesday, May 28, 2024. This trademark is owned by Synplogen Co., Ltd.. The COMBI-OGAB trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development relating to DNA synthesis technology; technical advisory services relating to DNA synthesis technology; research and development relating to production and analysis of virus vector; technological advisory services relating to production and analysis of virus vector; research and development relating to production and analysis of mRNA; technological advisory services relating to production and analysis of mRNA; research and development relating to gene therapy; technical advisory services relating to gene therapy research; technological advisory services relating to productization of gene therapy products; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, and technical advisory services relating thereto in the fields of protein, ant...
combi-ogab

General Information


Serial Number79372347
Word MarkCOMBI-OGAB
Filing DateFriday, March 31, 2023
Status700 - REGISTERED
Status DateTuesday, May 28, 2024
Registration Number7394363
Registration DateTuesday, May 28, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 12, 2024

Trademark Statements


Goods and ServicesResearch and development relating to DNA synthesis technology; technical advisory services relating to DNA synthesis technology; research and development relating to production and analysis of virus vector; technological advisory services relating to production and analysis of virus vector; research and development relating to production and analysis of mRNA; technological advisory services relating to production and analysis of mRNA; research and development relating to gene therapy; technical advisory services relating to gene therapy research; technological advisory services relating to productization of gene therapy products; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, and technical advisory services relating thereto in the fields of protein, antibody, vaccine, virus, virus vector, mRNA, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services relating to genome synthesis technology; research and development, and technical advisory services relating thereto in the fields of protein, vaccine, virus, virus vector, mRNA, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection, and research of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; quality testing, inspection, and research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; research and development relating to production and analysis of virus vector for others; research and development relating to gene therapy products for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; quality testing, inspection, and research in the fields of agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; research and development in the field of gene expression systems; research and development in the fields of microorganisms and cells; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; bacteriological research; biological research

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, June 23, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSynplogen Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP

Party NameSynplogen Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP

Party NameSynplogen Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events


Event DateEvent Description
Friday, June 23, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 27, 2023APPLICATION FILING RECEIPT MAILED
Thursday, June 22, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, December 27, 2023ASSIGNED TO EXAMINER
Wednesday, February 21, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, February 21, 2024NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, February 21, 2024NOTICE OF PUBLICATION
Tuesday, March 12, 2024PUBLISHED FOR OPPOSITION
Thursday, February 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 12, 2024NOTIFICATION PROCESSED BY IB
Tuesday, May 28, 2024REGISTERED-PRINCIPAL REGISTER
Thursday, June 27, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB